FamiCord significantly improves operating cash flow in Q2 2026 amid persistently challenging business environment
Published on 08/28/2026 at 07:13 | dgap, AD HOC NEWS| FamiCord AG / Key word(s): Half Year Report/Half Year Results 28.08.2026 / 07:13 CET/CEST The issuer is solely responsible for the content of this announcement. Group revenues remain largely unchanged at EUR 43.2 million in H1 2026 Operating cash flow increases significantly to EUR 3.4 million due to improvements in net working capital EBITDA down 13.8 percent to EUR 4.3 million on challenging business environment and higher cost base; Guidance for 2026 financial year confirmed Leipzig, 28 August 2026 – FamiCord AG, Europe's leading cell bank and the third largest worldwide, continued to face muted consumer sentiment and weaker new customer business amid a challenging economic environment in Europe, historically low birth rates and increasing cost pressure in several European markets. The Company maintained tight cost control and increased the share of subscription-based revenue, strengthening the resilience of its business model. In the first half of 2026, Group revenue remained broadly stable at EUR 43.2 million, down 0.9 percent year on year (H1 2025: EUR 43.6 million). The net amount of invoiced services (B2C) also remained broadly stable at EUR 37.1 million (H1 2025: EUR 37.4 million). Within this figure, the net amount of annual recurring prepayments again increased, rising by 8.5 percent to EUR 12.5 million (H1 2025: EUR 11.6 million), reflecting stable underlying demand for the Company's services. Overall, the ongoing shift from prepayment to subscription models reflects the challenging market environment. At the same time, FamiCord’s customers remain committed to long-term cell-banking services despite the broader economic uncertainty. The contract mix therefore continued to shift towards recurring models, as in previous quarters. While this supports the stability and visibility of the Group's long-term revenue base, revenue from prepaid renewals and extensions continued to decline, falling by 11.5 percent to EUR 3.3 million (H1 2025: EUR 3.8 million). Together with weaker new customer business, this meant that positive pricing effects and the higher share of subscription-based contracts were again insufficient to fully offset the lower contribution from prepaid contracts. In terms of new client acquisition, market weakness persisted across most of FamiCord’s markets in the second quarter. Only the Middle East and Hong Kong maintained their growth trajectory, while Romania, Turkey, the UK, Austria, Lithuania and Cyprus remained broadly in line with the 2025 level. In response, the Company has begun implementing targeted measures to improve efficiency and lead management processes and to strengthen selected sales channels EBITDA amounted to EUR 4.3 million in the first half of 2026 (H1 2025: EUR 5.0 million), corresponding to an EBITDA margin of 9.9 percent (H1 2025: 11.4 percent). However, looking at the second quarter alone, the Company increased EBITDA by 11.8 percent to EUR 2.1 million, with EBITDA stabilizing over the course of the quarter. These initial signs of margin stabilization reflect the positive effects of the Company's continued strict cost discipline, including lower marketing expenditure and the alignment of marketing activities with the weaker market environment. At the same time, the Company faced higher cost of sales year on year, partly due to the further ramp-up of its CDMO activities. These activities continued to develop positively, and the Company established additional customer relationships in the second quarter. The key figures for business development are as follows:
Contact: FamiCord AG Ingo Middelmenne Head of Investor Relations Phone: +49 (0174) 9091190 Email: ingo.middelmenne@famicord.com Company profile FamiCord (formerly Vita 34) was founded in Leipzig in 1997 and today is by far the leading cell bank in Europe and the third largest worldwide. As the first private umbilical cord blood bank in Europe and a pioneer in cell banking, the company has since offered the collection, logistics, processing and storage of stem cells from umbilical cord blood, umbilical cord tissue and other postnatal tissues as a full-service provider for cryopreservation. The donor's own cells are either applicable directly as a medicine or constitute as a valuable starting material for medical cell therapy and are kept alive in the vapor of liquid nitrogen. Customers from about 50 countries have already provided for the health of their families with around 1.5 million units of stored biological material at FamiCord. Furthermore, the Company is active in the area of Cell and Gene CDMO. 28.08.2026 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group. The issuer is solely responsible for the content of this announcement. The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. View original content: EQS News |
| Language: | English |
| Company: | FamiCord AG |
| Perlickstr. 5 | |
| 04103 Leipzig | |
| Germany | |
| Phone: | +49(0341)48792-40 |
| Fax: | +49(0341)48792-39 |
| E-mail: | ir@famicord.com |
| Internet: | www.famicord.com |
| ISIN: | DE000A0BL849 |
| WKN: | A0BL84 |
| Listed: | Regulated Unofficial Market in Dusseldorf, Frankfurt (Scale), Hamburg, Hanover, Munich, Stuttgart, Tradegate BSX |
| LEI Code: | 529900OEWA4GSZEZ4P40 |
| EQS News ID: | 2388950 |
| End of News | EQS News Service |
| |
en | DE000A0BL849 | FAMICORD AG | boerse | 70012057 |
